Why Faster Science Isn’t Always Better

The Paradox of Scientific Advancement in Modern Society

The assumption that scientific progress uniformly benefits humanity has long dominated policy discussions and academic discourse. However, this widely accepted premise deserves critical examination. While breakthrough discoveries have extended lifespans, reduced disease burden, and improved living standards across the globe, the acceleration of scientific knowledge creation simultaneously introduces complex challenges that demand sophisticated policy responses. Understanding whether we should continue investing in faster scientific progress requires examining both the remarkable achievements of modern research and the potential dangers inherent in its rapid acceleration.

Reconsidering the Default Position on Scientific Benefit

For decades, economists and policymakers have treated technological innovation as almost universally positive, with only narrow exceptions acknowledged for specific domains like climate-related technologies. This consensus rests on compelling historical evidence: vaccines have saved hundreds of millions of lives, agricultural innovations have prevented famines, and medical breakthroughs have transformed previously fatal conditions into manageable diseases. Yet accepting scientific progress as inherently good without deeper scrutiny creates intellectual blind spots.

The challenge emerges when considering that scientific discovery itself remains morally neutral. Science is fundamentally a tool—it reveals how the natural world operates. The applications of that knowledge, however, carry profound moral weight. A single scientific breakthrough might enable life-saving therapies or create devastating weapons. The same understanding of genetic systems that allows researchers to cure inherited diseases also potentially enables the creation of dangerous engineered pathogens. This moral neutrality of science itself suggests that the value proposition requires careful temporal and contextual analysis.

The Timeline Problem: When Benefits Materialize Against Risks

A crucial framework for evaluating scientific acceleration involves understanding when benefits versus risks emerge. Consider a scenario where improved peer review systems and strategic funding mechanisms accelerate scientific progress by approximately ten percent. Over a single year, this acceleration might seem minor. However, compounded over a decade, this modest acceleration could advance humanity’s scientific frontier by several additional years.

The risk calculus becomes apparent when considering dangerous applications. Suppose a particular scientific advancement—perhaps in synthetic biology or artificial intelligence—enables capabilities that bad actors could weaponize. If conventional research timelines would have produced this dangerous capability in year ten, but accelerated research brings it forward to year nine, the consequence is that potential harm arrives one year earlier. If that harm is catastrophic, advancing its arrival even by a single year might entirely erase the cumulative benefits gained from years of accelerated beneficial research.

This temporal framework reveals why blanket acceleration policies might be counterproductive. The timing mismatch between when beneficial applications emerge versus when dangerous applications become accessible creates a potentially negative risk-benefit calculation, particularly for dual-use technologies.

Dual-Use Technologies: The Central Challenge

Advanced biotechnology represents one of the most significant dual-use domains in contemporary science. The same techniques enabling the development of personalized cancer treatments or therapies for rare genetic diseases can potentially be applied to create dangerous pathogens. The knowledge required to develop such threats has become progressively more latent within the scientific literature. As artificial intelligence capabilities advance, the ability to synthesize this distributed knowledge and apply it toward harmful ends increases substantially.

The concerning reality is that the underlying scientific knowledge enabling dangerous applications may already exist, dispersed throughout the research literature and institutional memory of the scientific community. In this scenario, accelerating general scientific progress may disproportionately benefit potential bad actors, as they can leverage the expanding toolkit of techniques and computational methods without the institutional constraints governing legitimate research.

This asymmetry—where acceleration benefits diffuse actors with coordinating institutions less than it benefits focused actors with malicious intent—represents a fundamental challenge to simplistic pro-acceleration policies.

Pathways to Better, Rather Than Merely Faster, Science

Rather than pursuing broad acceleration across all scientific domains, evidence suggests that targeted improvements in the scientific process itself offer superior outcomes. Research into metascience—the study of how science works—provides insights into optimizing research quality, relevance, and safety simultaneously.

Strategic funding mechanisms represent one lever for improvement. By directing resources toward research addressing humanity’s most pressing challenges while simultaneously considering risks, funding bodies can shift the composition of scientific activity. This approach differs fundamentally from merely providing more money for all research, which accelerates progress across beneficial and potentially harmful domains indiscriminately.

Additionally, improving peer review processes and implementing better mechanisms for identifying high-quality researchers can enhance scientific productivity without pure acceleration. If peer reviewers could be selected based on demonstrated forecasting ability—identifying those individuals particularly skilled at recognizing research quality and impact—the result would be more targeted scientific progress. Better selection of which research to fund and which researchers to support creates a more favorable risk-benefit profile than simple acceleration.

Can Better Science Address Existential Risks?

An intriguing counterargument suggests that sufficiently advanced scientific capabilities might enable humanity to address catastrophic risks preemptively. For instance, revolutionary scientific breakthroughs could produce solutions that governments and large coordinating bodies might implement globally. Examples include vaccine platforms that could address emerging pandemic threats or technological approaches to managing global risks.

The mRNA vaccine platform illustrates this possibility. The underlying science enabling rapid vaccine development against novel pathogens represents exactly the kind of frontier scientific capability that becomes available only after sustained research investment and breakthrough discovery. Faster access to such general capabilities could theoretically allow humanity to implement coordinated responses to emerging threats more rapidly.

However, this optimistic scenario requires several conditions. First, the specific scientific breakthroughs must address actual threats. Second, these breakthroughs must be scalable to global implementation by coordinating institutions. Third, the benefits must materialize before dangerous applications of the same scientific advancement become accessible to bad actors. These constraints suggest that while science can contribute to risk management, relying exclusively on scientific solutions to existential risks may prove insufficient.

The Institutional Asymmetry Problem

A fundamental reality shapes the risk-benefit analysis: cutting-edge scientific discoveries typically require coordination among hundreds or thousands of researchers working within institutional constraints, peer review systems, and governance frameworks. By contrast, many dangerous applications might be pursued by much smaller groups with weaker institutional constraints.

This asymmetry means that acceleration affects the availability of frontier capabilities differently depending on who pursues them. Legitimate research organizations face barriers—institutional review boards, ethical constraints, publishing norms, and coordination requirements—that smaller groups pursuing malicious applications might avoid. Accelerating science across the board reduces the institutional advantage that constrains dangerous applications more than it advantages beneficial ones.

Addressing this asymmetry might require not just better science policy but also attention to biosecurity, information security, and institutional frameworks that maintain advantages for beneficial applications while constraining dangerous ones.

Long-Term Considerations and Temporal Discounting

Evaluating long-term consequences requires acknowledging that predicting scientific returns decades into the future involves substantial uncertainty. The value of science depends heavily on future conditions. In scenarios of abundant frontier breakthroughs, accelerating science becomes highly valuable. Conversely, in scenarios where science increasingly enables bad actors without proportional benefits to coordinating institutions, acceleration becomes harmful.

These divergent scenarios are not merely theoretical. During historical periods of intense international competition and conflict, scientific advances accelerated weapons development more than beneficial applications. The potential for future periods of greater international tension or instability cannot be dismissed.

Metascience: Improving How We Conduct Science

Investment in understanding how science works—metascience—offers a complementary approach to direct acceleration. Research examining which peer review systems identify high-impact research, how institutional structures affect scientific productivity, or what funding mechanisms most effectively target important problems can improve scientific efficiency without necessarily accelerating all research.

These improvements in scientific process could concentrate advancement in beneficial domains while leaving risky research either unconsidered or subjected to enhanced scrutiny. This targeted approach acknowledges that science is not monolithic—different domains carry different risk profiles and merit different policy approaches.

Frequently Asked Questions

Is all scientific progress beneficial for humanity?

No. While much scientific progress has improved human welfare substantially, science itself is morally neutral. The same discoveries can enable both beneficial and harmful applications, particularly in dual-use domains like biotechnology. The question is not whether science is good, but whether accelerating it in its current configuration optimally serves human interests.

How does accelerating science specifically increase risks?

Acceleration compresses timelines. If dangerous applications arrive alongside beneficial ones, advancing both by several years might have catastrophic consequences if the danger materializes. Additionally, bad actors pursuing malicious applications may benefit disproportionately from acceleration since they face fewer institutional constraints than legitimate research organizations.

Can targeted science address existential risks?

Potentially. Sufficiently advanced scientific capabilities might enable solutions that large coordinating bodies implement globally. However, this requires that scientific breakthroughs address actual threats, that they’re scalable, and that they materialize before dangerous applications become widely accessible.

What is metascience and why does it matter?

Metascience is the study of how science works. By understanding which peer review systems, institutional structures, and funding mechanisms produce the most valuable research, we can improve science quality without blanket acceleration, potentially concentrating benefits in safer domains.

Should we stop funding scientific research?

Not necessarily. The argument suggests a more nuanced approach: funding science strategically, targeting domains with clear benefits while implementing safeguards for dual-use research, and improving scientific process through metascience research. The goal is better science, not necessarily faster science.

Written by

Medha Deb

Medha Deb is an editor with a master's degree in Applied Linguistics from the University of Hyderabad. She believes that her qualification has helped her develop a deep understanding of language and its application in various contexts. Medha specializes in the areas of beauty, health, sports, and wellness and is committed to ensuring that the content on the website is…